We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Regeneron (REGN - Free Report) closed at $800.73, marking a +0.33% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.09%. Elsewhere, the Dow gained 0.07%, while the tech-heavy Nasdaq added 0.98%.
Coming into today, shares of the biopharmaceutical company had lost 0.51% in the past month. In that same time, the Medical sector gained 4.5%, while the S&P 500 gained 4.59%.
Regeneron will be looking to display strength as it nears its next earnings release, which is expected to be May 4, 2023. The company is expected to report EPS of $9.44, down 17.84% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $2.92 billion, down 1.36% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $40.74 per share and revenue of $12.48 billion. These totals would mark changes of -9.43% and +2.53%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Regeneron. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.84% lower. Regeneron currently has a Zacks Rank of #3 (Hold).
Investors should also note Regeneron's current valuation metrics, including its Forward P/E ratio of 19.59. This represents a discount compared to its industry's average Forward P/E of 20.65.
Meanwhile, REGN's PEG ratio is currently 1.96. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. REGN's industry had an average PEG ratio of 1.88 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 80, putting it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Regeneron (REGN - Free Report) closed at $800.73, marking a +0.33% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.09%. Elsewhere, the Dow gained 0.07%, while the tech-heavy Nasdaq added 0.98%.
Coming into today, shares of the biopharmaceutical company had lost 0.51% in the past month. In that same time, the Medical sector gained 4.5%, while the S&P 500 gained 4.59%.
Regeneron will be looking to display strength as it nears its next earnings release, which is expected to be May 4, 2023. The company is expected to report EPS of $9.44, down 17.84% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $2.92 billion, down 1.36% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $40.74 per share and revenue of $12.48 billion. These totals would mark changes of -9.43% and +2.53%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Regeneron. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.84% lower. Regeneron currently has a Zacks Rank of #3 (Hold).
Investors should also note Regeneron's current valuation metrics, including its Forward P/E ratio of 19.59. This represents a discount compared to its industry's average Forward P/E of 20.65.
Meanwhile, REGN's PEG ratio is currently 1.96. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. REGN's industry had an average PEG ratio of 1.88 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 80, putting it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.